forex_managed_account_1

GW Pharmaceuticals doubles in value after cannabis drug success in epilepsy trial

Discussion in 'Market News' started by Lily, Mar 14, 2016.

  1. Lily

    Lily Forum Member

    Joined:
    Aug 29, 2015
    Messages:
    8,337
    Likes Received:
    0
    Company now seeking talks with US regulators about approval for treatment

    An experimental cannabis-based drug from GW Pharmaceuticals has successfully treated children with a rare form of epilepsy, sending the company’s shares soaring and more than doubling its stock market value.

    GW said a clinical trial showed its Epidiolex drug had significantly reduced seizures in patients with Dravet syndrome, a type of epilesy for which there are currently no treatments approved in the US, compared to a placebo. In the trial of 120 patients, those taking Epidiolex saw a reduction of monthly convulsive seizures of 39% compared with 13% for a placebo, which GW said was highly statistically significant. The company’s chief executive Justin Gover said:

    The positive outcome of this Phase 3 trial is a significant milestone in the development of Epidiolex as a potential new treatment for patients suffering from Dravet syndrome. We are excited about the potential for Epidiolex to become the first [US Food and Drug Administration] approved treatment option specifically for Dravet syndrome patients and their families.

    Continue reading...
     

Share This Page

free forex signals